John J. Brewington, MD

Member, Division of Pulmonary Medicine

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-636-6771

Email john.brewington@cchmc.org

Clinical

Pulmonary medicine; bronchology; cystic fibrosis; congenital airway malformations

Research

Cystic fibrosis; CFTR modulators; patient-derived model systems

Dr. Brewington cares for patient with a wide variety of airway and lung diseases. He has a particular interest in the care of patients with cystic fibrosis, congenital airway malformations, and chronic respiratory failure. His research focuses primarily on cystic fibrosis, with a goal of maximizing the clinical benefits of new "modulator" drugs at the individual patient level. His work investigates possible drug-drug interactions between traditional CF therapies and these novel drugs, as well as personalized model systems to predict and study drug benefit for an individual patient. He is also interested in medical education, including residency and fellowship training, as well as formal training in flexible bronchoscopy.

MD: Wake Forest University, Winston-Salem, NC, 2009.

Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2012.

Chief Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2013.

Fellowship: Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2016.

Certification: Pediatrics, 2012; Pediatric Pulmonary Medicine, 2016.

View PubMed Publications

Brewington JJ, Filbrandt ET, LaRosa FJ, Moncivaiz JD, Ostmann AJ, Strecker LM, Clancy JP. Brushed Nasal Epithelial Cells as a Proxy for Bronchial Epithelial CFTR Studies. JCI Insight. 2018 Jul 12;3(13).

Brewington JJ, Filbrandt ET, LaRosa FJ, Moncivaiz JD, Ostmann AJ, Strecker LM, Clancy JP. Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study. J Vis Exp. 2018 Apr 11;(134).

McCarthy C, Brewington JJ, Harkness B, Clancy JP, Trapnell BC. Personalized CFTR Pharmacotherapeutic Response Testing and Therapy of Cystic Fibrosis. Eur Respir J. 2018 Jun 7;51(6)

Brewington JJ, Backstrom J, Feldman A, Kramer EL, Moncivaiz JD, Ostmann AJ, Zhu X, Lu JL, Clancy JP. Chronic beta 2 adrenergic receptor stimulation limits CFTR activation in human airway epithelia. JCI Insight. 2018 Feb 22;3(4).

Brewington JJ, Filbrandt ET, LaRosa FJ, Ostmann A, Strecker LM, Szczesniak RD, Clancy JP. Detection of CFTR Function and Modulation in Primary Human Nasal Cell Spheroids. J Cyst Fibros. 2018 Jan;17(1):26-33.

Zak S, Clancy JP, Brewington JJ. CFTR Functional Assays in Drug Development. Expert Opin Orphan Drugs. 2017 Oct;5(11):889-898.

Parker MW, Carroll M, Ballinger J, Bolser B, Brewington JJ, Campanella S, Davis-Sandfoss A, Tucker K, Brady PW. Implementation of a Communication Bundle for High-Risk Patients. Hosp Pediatr. 2017 Sep;7(9):523-529.

Brewington JJ, Clancy JP. Diagnostic Testing in Cystic Fibrosis. Clinics in Chest Medicine. 2016 Mar;37(1):31-46.

Brewington JJ, McPhail GL, Clancy JP. Lumacaftor: Preclinical and Clinical Trial Experience of Phe508del CFTR Correction. Expert Rev Respir Med. 2016 Jan;10(1):5-17.

Siracusa CM, Brewington JJ, Brockbank JC, Guilbert TW. Update in Pediatric Lung Disease 2014. Am J Respir Crit Care Med. 2015 Oct;192(8):918-923.

Sensitivity of Corrected F508del CFTR Function to Chronic Beta Adrenergic Receptor Stimulation. Principal Investigator. Cystic Fibrosis Foundation. July 2016-June 2019.

Personalizing Cystic Fibrosis Research Translation. Translational Core Director. Cystic Fibrosis Foundation. July 2015-June 2019.

Development of Personalized Model Systems Using ROCKi Expanded Human Nasal Epithelial Cells. Principal Investigator. Cystic Fibrosis Foundation. July 2015-June 2019.

A Single Cell Mapping of Nasal Epithelial Cells from CF vs Non-CF Patients. Co-Investigator (Xu). Cystic Fibrosis Foundation Therapeutics. July 2018-June 2020.